Recombinant antibody production leveraging Chinese Hamster Ovary (CHO) cells presents a critical platform for the development of therapeutic monoclonal antibodies. Enhancing this process is essential to achieve high yields and quality antibodies. A variety of strategies can be utilized to optimize antibody production in CHO cells. These include bi